Cincor Pharma, Inc.

( )
CINC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.93%54.040.9%$2015.04m
JNJJohnson & Johnson -0.82%165.210.7%$968.47m
ABBVAbbVie, Inc. -1.62%133.021.9%$895.75m
MRKMerck & Co., Inc. -0.69%80.730.7%$855.87m
BMYBristol-Myers Squibb Co. -0.17%64.611.0%$688.01m
LLYEli Lilly & Co. -0.76%243.201.1%$618.76m
AZNAstraZeneca Plc 1.16%60.171.0%$241.82m
NVSNovartis AG -0.75%88.180.2%$194.25m
GSKGlaxoSmithKline Plc -1.77%44.880.2%$162.29m
NVONovo Nordisk A/S -1.86%95.480.1%$152.14m
VTRSViatris, Inc. -0.54%14.640.0%$140.27m
RGENRepligen Corp. -0.59%188.466.7%$99.30m
IMMXImmix Biopharma, Inc. -4.24%5.420.0%$85.02m
ALLKAllakos, Inc. -3.37%7.180.0%$84.68m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.87%116.040.0%$72.25m

Company Profile

CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism; as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Boston, MA.